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INTRODUCTION
From an epidemiological and methodological standpoint the
comparison of antimicrobial resistance in different countries of
the European Union (EU) is extremely difficult, since unbiased
assessment is complicated. There are many reasons for these
difficulties. Different antimicrobial agents are tested; different
systems and different breakpoints for antimicrobial susceptibility
testing are used; data from point-prevalence studies are used for
longitudinal comparisons (e.g. studies on antibiotic resistance
performed in 1970 and 1990), in spite of major differences in
study conditions and methodology; frequently only resistant
strains from selected materials are tested. Finally, differences
between the prevalence of resistant strains from local practices
and university hospitals are not taken into account.
In order to obtain more comparable and reliable data, the
European Commission has funded a European Antimicrobial
Resistance Surveillance System (EARSS). This system, in
which all member states of the European Union, plus Iceland
and Norway participate, is co-ordinated by the National Insti-
tute of Public Health and the Environment of the Netherlands
(RIVM). In Table 1 a number of European projects on anti-
microbial resistance surveillance are listed. EARSS, which is
financed by the EU, differs from other projects because it
does not collect and test strains centrally but collects data from
participating laboratories (Figure 1). It will be an ongoing sur-
veillance system collecting and analyzing data at national and
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international level. EARSS intends to contribute to the quality
of antimicrobial resistance surveillance in the local laboratories.
More than 400 laboratories have agreed to participate in this
European communicable disease network. In this paper the
methodology used within EARSS is discussed, especially with
regard to the epidemiological and microbiological difficulties
already mentioned.
STRUCTURE
EARSS is an international network of national surveillance
systems which aims to aggregate comparable and reliable anti-
microbial resistance data for public health purposes in Europe.
These national surveillance systems are based on output that can
routinely be harvested from the diagnostic laboratory without
changing the primary diagnostic process. All participating coun-
tries have appointed a national representative microbiologist
and epidemiologist. They work together to use aggregated data
sets for more complex epidemiological studies. One rep-
resentative of each member state acts as national co-ordinator,
whose main tasks are the co-ordination of participating lab-
oratories, distribution and collection of the questionnaire on
susceptibility testing and collecting and forwarding resistance
data for international collation quarterly.
Pilot-study
On basis of criteria such as public health relevance, all present
at the first EARSS meeting (18–20 May, 1998), agreed that
Staphylococcus aureus and Streptococcus pneumoniae are the most
relevant pathogens for the pilot phase in EARSS. In order to
minimize sample bias, it was decided to test only Streptococcus
pneumoniae isolates from blood and cerebrospinal fluid (CSF),
and Staphylococcus aureus isolates from blood for antimicrobial
resistance.
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Table 1 Antimicrobial resistance surveillance projects in Europe
Collection of
Pathogens Funding strains data Remarks
Alexander project Streptococcus pneumoniae, Pharmaceutical industry Yes No Collection of strains every year
Haemophilus influenzae,
Moraxella catarrhalis
Artemis Study In relation to macrolide use Pharmaceutical industry Yes No World-wide
EARSS Staphylococcus aureusa, EU (DG V) No Yes Determination of antimicrobial sus-
Streptococcus pneumoniaea ceptibility in local laboratories
Enter-net (Salmnet) Salmonella spp. EU (BIOMED) No Yes Determination of antimicrobial sus-
ceptibility in reference laboratories
EuroTB Mycobacterium tuberculosis EU (DG V) No Yes Surveillance of resistance in start-up
phase
Harmony MRSA, VRE, EU (DG XII) No Yes Emphasis on molecular biology
Clostridium difficile
INSPEAR Staphylococcus aureus CDC/EMC No Yes Concerted action USA/EU
Mystic In relation to meropenem use Pharmaceutical industry No Yes World-wide
Resistance Web All relevant pathogens Pharmaceutical industry No Yes Electronic data collection and feedback
SARISA Staphylococcus aureus Pharmaceutical industry Yes No Relation between resistance and
usage is subject of research
SENTRY (ENARE) Streptococcus pneumoniae, Pharmaceutical industry Yes No Emphasis on molecular biology
H. influenzae, (ENARE was financed
M. catarrhalis by the EU)
TSN (MRL) All relevant pathogens Pharmaceutical industry No Yes Electronic data collection and feedback
WARN Staphylococcus aureus, National government No Yes Starting with Czech Republic
Streptococcus pneumoniae,
Enterococcus spp.
WHO/GASP Neisseria gonorrhoeae World Health Organization – – Emphasis on standardization and
improvement of methodology
WHO/IUATLD M. tuberculosis World Health Organization No Yes Status unknown
a in the pilot-study.
EU, European Union; CDC/EMC, Centre for Diseases Control/Emerging and other Communicable Diseases Surveillance and Control (WHO).
Figure 1 Structure of the European Antimicrobial Resistance Surveillance System.
PROTOCOLS FOR TESTING
Staphylococcus aureus
The objective is to study the methicillin-resistance of Staphy-
lococcus aureus in blood isolates in hospitals in Europe using
resistance data on the first isolate only of each strain from the
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blood of each patient (‘patient-isolate’) with a hospital-acquired
Staphylococcus aureus infection (confirmed by a coagulase test).
The protocol is illustrated in Figure 2.
Oxacillin screen plates (6 mg/L according to NCCLS) or
oxacillin disks (1 mg or 5 mg) are used. When 1 mg oxacillin
(NCCLS) is used, nonsusceptible isolates have a zone size of
10 mm. When 5 mg oxacillin (according to the French guide-
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Figure 2 Protocol for testing susceptibility of Staphylococcus aureus.
lines, SFM) is used, nonsusceptible isolates have a zone size of
19 mm.
In the case of oxacillin-nonsusceptible Staphylococcus aureus,
either the local participating laboratories or a reference lab-
oratory additionally determine the minimum inhibitory con-
centrations (MICs) for oxacillin and vancomycin (range of
dilutions: 0.016–256 mg/L), specifying whether agar-dilution,
microdilution or E-test are used, or the polymerase chain reac-
tion (PCR) for the mecA-gene.
Streptococcus pneumoniae
The objective is to study the penicillin resistance of Streptococcus
pneumoniae blood and CSF isolates in Europe using resistance
data on the first isolate only from the blood or CSF of each
patient with a community acquired Streptococcus pneumoniae
(indentification confirmed by optochin test) infection. The
protocol is illustrated in Figure 3.
For testing of Streptococcus pneumoniae oxacillin disks (1 mg,
NCCLS or 5 mg, SFM) are used. Non-susceptible strains have
a zone size of 20 mm for 1 mg and 26 mm for 5 mg.
In the case of oxacillin nonsusceptible Streptococcus pneu-
moniae, either the local participating laboratories or the
reference laboratory additionally determine the MICs for peni-
cillin, cefotaxime or ceftriaxone and ciprofloxacin (range of
dilutions: 0.016–256 mg/L (penicillin) or 0.002–32 mg/L
(cefotaxime/ceftriaxone and ciprofloxacin)), specifying
whether agar-dilution, microdilution or E-test is used.
QUALITY ASSURANCE
A quality assurance scheme is essential so that a comparative
evaluation can be performed within and between countries,
taking into consideration the number of participating
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laboratories in each country, and the local situation regarding
test procedures. A minimal set of reference strains is sent out
from a central facility, and every participating laboratory must
study them repeatedly, preferably every month under the same
conditions as those used for their own strains. At this time
point, the exact quality assurance scheme is discussed by the
advisory board of EARSS. After consultation of the national
co-ordinators, it will be implemented next year. More infor-
mation is available on the web site.
SELECTION OF PARTICIPATING LABORATORIES
EARSS included sufficient laboratories to cover at least 20% of
the total population or 20% of the total number of annual bed
days for each country. With over 400 laboratories participating
in EARSS, the coverage is well over 20% of the population in all
participating countries. Most are first-line clinical laboratories in
which both academic and nonacademic hospitals are rep-
resented and the patient spectrum ranges from nursing homes
to tertiary referral hospitals.
EPIDEMIOLOGICAL DATA
EARSS collects the following information by means of isolate
record forms and questionnaire.
Isolate record form
The following information is required: sex, month and year of
birth, date of sample collection, name or code of hospital,
hospital department, origin of patient, isolate sample number,
laboratory code, and antibiotic susceptibility testing results.
Other optional information is clinical diagnosis, and antibiotic
susceptibility data for other antibiotics.
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Figure 3 Protocol for testing susceptibility of Streptococcus pneumoniae.
Questionnaire on susceptibility testing
This questionnaire provides information on test methods used,
and collects denominator data of the laboratory, and of the
hospital(s) served by one laboratory. The hospital facilities
(ICU, renal, transplant, cardiac surgery) are described. For com-
munity acquired pathogens the catchment population of the
laboratory is denominator. For nosocomial pathogens the num-
ber of bed days is the denominator.
Patient and isolate information can be related to laboratory
and hospital information by means of the unique laboratory
code on all isolate record forms and questionnaires.
DISCUSSION
EARSS is carefully designed in order to avoid the epi-
demiological and microbiological fallacies summarized in the
introduction.
Two pathogens only, Staphylococcus aureus and Streptococcus
pneumoniae, are tested against a restricted set of specified anti-
microbials. The choice of oxacillin, instead of methicillin, for
determination of MRSA (ORSA) is determined by methicillin
becoming unavailable. For Streptococcus pneumoniae, testing of
oxacillin, as a first step, in combination with a penicillin MIC
for nonsusceptibles is now generally accepted [1]. We believe
that the introduction of a new generation of fluoroquinolones
for the therapy of respiratory tract infections necessitates a fol-
low-up of ciprofloxacin resistance in Streptococcus pneumoniae.
The protocols for Streptococcus pneumoniae and Staphylococcus
aureus are clearly defined. After simple first-line screening the
MIC is determined. Such a protocol combines easy accessibility
with careful quantitative examination of antimicrobial resist-
ance. The disk diffusion test does not always lead to comparable
results, because of differences in inoculum, medium, time of
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incubation and use of CO2. Thus, it is important to know
what are the test procedures in each individual participating
laboratory, in order to check and account for these differences.
For reliable detection of resistance to oxacillin in Staphy-
lococcus aureus, oxacillin agar screen plates can be used [2,3], but
results from the questionnaire show that they are only used in
a few countries. For that reason, we accept data from the
oxacillin disk diffusion test [3,4].
The standard for confirmation of a suspected MRSA is testing
for the presence of the mecA-gene. When a participating lab-
oratory is not able to perform a PCR, determination of the
oxacillin MIC is carried out for presumptive confirmation of
the strain as an MRSA, and the strain may be sent to a reference
laboratory for PCR.
Vancomycin-intermediate MRSA (VISA) strains, which
were first reported in Japan [5,6], are often heterogeneously
resistant. The presence of these VISA can be missed when
measuring an MIC under standard conditions, but there is no
established protocol to test for them. In addition, the relevance
of this intermediate resistance to vancomycin for vancomycin
therapy of MRSA can be disputed. In case of vancomycin MIC
testing in MRSA we prefer a standardized protocol which is
also used for oxacillin MICs, realizing that some VISA strains
might be missed. In case of using the E-test we recommend to
follow the guidelines of the producer. If VISA strains are
detected, further analysis (e.g. sequence analysis) will be per-
formed.
Breakpoints are defined in the two protocols, according to
NCCLS or in some cases to SFM (French) or Swedish Ref-
erence Group for Antibiotics (SRGA) (Swedish) guidelines,
but the validity of these breakpoints is checked by several
procedures within the protocol. For all Streptococcus pneumoniae
and Staphylococcus aureus isolates, participating laboratories
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record (when possible) the inhibition zone (in case of the disk
method). This will give more insight into the distribution of
susceptible, low-level and high-level resistant Streptococcus
pneumoniae or Staphylococcus aureus strains [7]. In addition, the
distribution of zone diameters is used to study the quality of
resistance data from different participating laboratories [8].
The second step, MIC testing, validates the categorization of
the strains as susceptible or nonsusceptible, according to the
SFM and the NCCLS guidelines, and corrects false positive
(resistant) results. Monthly testing of quality control strains
assesses correct use of breakpoints for the categorization of
strains into susceptible and resistant.
EARSS will collect data continuously with the purpose of
performing longitudinal analysis on developments in anti-
microbial resistance. It is necessary for the national co-ord-
inators to update their information regularly on the techniques
used for antimicrobial susceptibility testing by the first-line
laboratories, in order to detect any changes in techniques used
for antimicrobial susceptibility testing.
Resistance surveillance on the basis of the whole range of
routine samples may overestimate the resistance problem [9,10].
The EARSS pilot-study is therefore restricted to invasive
isolates, which are routinely tested for antimicrobial suscep-
tibility.
The participating laboratories, serving university hospitals,
small regional hospitals and general practitioners, provide the
national co-ordinators with information on the number of pati-
ent-days of every hospital they serve and the catchment popu-
lation.
The first result of EARSS is that the system has stimulated
several countries to establish or to update their national resist-
ance surveillance system in order to follow national resistance
patterns and to compare these with developments in Europe.
We believe that it can be a good framework in the European
Union for monitoring antimicrobial resistance in the future.
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